1.71
price down icon2.29%   -0.04
after-market After Hours: 1.65 -0.06 -3.51%
loading

Fortress Biotech Inc Stock (FBIO) Latest News

pulisher
04:19 AM

Mustang Bio Regains Compliance with Nasdaq Minimum Bid Price Requirement - The Manila Times

04:19 AM
pulisher
Feb 10, 2025

Mustang Bio Closes $8 Million Public Offering - citybiz

Feb 10, 2025
pulisher
Feb 10, 2025

Mustang Bio Announces Closing of $8 Million Public Offering - GlobeNewswire

Feb 10, 2025
pulisher
Feb 10, 2025

Mustang Bio Announces Closing of $8 Million Public Offering - GlobeNewswire Inc.

Feb 10, 2025
pulisher
Feb 07, 2025

Mustang Bio sets terms for $8M public offering - MSN

Feb 07, 2025
pulisher
Feb 06, 2025

Mustang Bio Announces Pricing of $8 Million Public Offering - The Manila Times

Feb 06, 2025
pulisher
Feb 05, 2025

Fortress Biotech (NASDAQ:FBIOP) Trading Up 0.3% – Still a Buy? - Defense World

Feb 05, 2025
pulisher
Jan 31, 2025

Mustang Bio stock plunges to 52-week low of $4 - MSN

Jan 31, 2025
pulisher
Jan 29, 2025

Triplex vaccine enters Phase 2 trial in stem cell donors - MSN

Jan 29, 2025
pulisher
Jan 28, 2025

Fortress Biotech announces first patient dosed in Phase 2 trial of Triplex - Yahoo Finance

Jan 28, 2025
pulisher
Jan 28, 2025

Fortress doses first subject in Phase II CMV vaccine trial - Clinical Trials Arena

Jan 28, 2025
pulisher
Jan 28, 2025

Fortress Biotech Announces First Patient Dosed in Phase 2 - GlobeNewswire

Jan 28, 2025
pulisher
Jan 27, 2025

Fortress Biotech (FBIO) Announces First Patient Dosed in Phase 2 Clinical Trial of Triplex Vaccination - StreetInsider.com

Jan 27, 2025
pulisher
Jan 27, 2025

Fortress Biotech Announces First Patient Dosed in Phase 2 Clinical Trial of Triplex Vaccination in Stem Cell Donors to Reduce CMV Events in Recipients of HSCT - Yahoo Finance

Jan 27, 2025
pulisher
Jan 25, 2025

(FBIOP) Investment Analysis - Stock Traders Daily

Jan 25, 2025
pulisher
Jan 24, 2025

FBIOFortress Biotech, Inc. Latest Stock News & Market Updates - StockTitan

Jan 24, 2025
pulisher
Jan 19, 2025

Fortress Biotech, Inc. (NASDAQ:FBIO) Sees Large Increase in Short Interest - MarketBeat

Jan 19, 2025
pulisher
Jan 19, 2025

Fortress Biotech (NASDAQ: FBIO) Receives Notification of Extended FDA Target Action Date for CUTX-101 - Defense World

Jan 19, 2025
pulisher
Jan 18, 2025

Boom Or Bust: What Are Fortress Biotech Inc’s (NASDAQ:FBIO) Future Prospects? - Marketing Sentinel

Jan 18, 2025
pulisher
Jan 17, 2025

FDA extends review of Fortress Biotech's CUTX-101 drug - MSN

Jan 17, 2025
pulisher
Jan 17, 2025

FDA extends review of Fortress Biotech's CUTX-101 drug By Investing.com - Investing.com Canada

Jan 17, 2025
pulisher
Jan 15, 2025

Microsoft Corp (MSFT-Q) QuotePress Release - The Globe and Mail

Jan 15, 2025
pulisher
Jan 14, 2025

How the (FBIOP) price action is used to our Advantage - Stock Traders Daily

Jan 14, 2025
pulisher
Jan 14, 2025

Mustang Bio announces 1-for-50 reverse stock split By Investing.com - Investing.com Canada

Jan 14, 2025
pulisher
Jan 14, 2025

Mustang Bio announces 1-for-50 reverse stock split - Investing.com India

Jan 14, 2025
pulisher
Jan 14, 2025

Geode Capital Management LLC Boosts Holdings in Fortress Biotech, Inc. (NASDAQ:FBIO) - Defense World

Jan 14, 2025
pulisher
Jan 14, 2025

Mustang Bio Announces Reverse Stock Split - Yahoo Finance

Jan 14, 2025
pulisher
Jan 13, 2025

Insiders Enjoy US$156k Return After Buying Fortress Biotech Stock - Simply Wall St

Jan 13, 2025
pulisher
Jan 10, 2025

Drug to treat rare pediatric disease accepted for FDA review - The Business Journals

Jan 10, 2025
pulisher
Jan 07, 2025

Fortress Biotech subsidiary's drug application accepted by FDA - Investing.com Australia

Jan 07, 2025
pulisher
Jan 07, 2025

Fortress Biotech’s Subsidiary Cyprium Therapeutics Receives FDA Acceptance for CUTX-101 NDA Review - Defense World

Jan 07, 2025
pulisher
Jan 06, 2025

Fortress Biotech subsidiary's drug application accepted by FDA By Investing.com - Investing.com South Africa

Jan 06, 2025
pulisher
Jan 06, 2025

Sentynl Therapeutics Announces U.S. FDA Acceptance and Priority Review of New Drug Application for CUTX-101 (Copper Histidinate) Product Candidate for Treatment of Menkes Disease - The Eastern Progress Online

Jan 06, 2025
pulisher
Jan 06, 2025

Fortress Biotech and Cyprium Therapeutics Announce U.S. FDA - GlobeNewswire

Jan 06, 2025
pulisher
Jan 06, 2025

Fortress Biotech (FBIO) and Cyprium Therapeutics Announce U.S. FDA Acceptance and Priority Review of NDA for CUTX-101 - StreetInsider.com

Jan 06, 2025
pulisher
Jan 06, 2025

Fortress Biotech and Cyprium Therapeutics Announce U.S. FDA Acceptance and Priority Review of NDA for CUTX-101 for Treatment of Menkes Disease - Yahoo Finance

Jan 06, 2025
pulisher
Jan 01, 2025

Fortress Biotech (NASDAQ:FBIO) Stock Price Passes Above 200-Day Moving Average – What’s Next? - Defense World

Jan 01, 2025
pulisher
Jan 01, 2025

Fortress Biotech (NASDAQ:FBIO) Share Price Passes Above 200-Day Moving AverageHere's What Happened - MarketBeat

Jan 01, 2025
pulisher
Dec 27, 2024

Head to Head Contrast: Tyra Biosciences (NASDAQ:TYRA) and Checkpoint Therapeutics (NASDAQ:CKPT) - Defense World

Dec 27, 2024
pulisher
Dec 24, 2024

When the Price of (FBIOP) Talks, People Listen - Stock Traders Daily

Dec 24, 2024
pulisher
Dec 17, 2024

Fortress Biotech subsidiary gains FDA approval for cSCC therapy - Investing.com

Dec 17, 2024
pulisher
Dec 17, 2024

Fortress Biotech subsidiary gains FDA approval for cSCC therapy By Investing.com - Investing.com UK

Dec 17, 2024
pulisher
Dec 14, 2024

Objective long/short (FBIOP) Report - Stock Traders Daily

Dec 14, 2024
pulisher
Dec 13, 2024

Checkpoint Therapeutics Announces FDA Approval of UNLOXCYT™ (cosibelimab-ipdl) - GlobeNewswire

Dec 13, 2024
pulisher
Dec 13, 2024

Checkpoint Therapeutics Secures First FDA Approval for Novel Cancer Drug UNLOXCYT in $1B+ Market - StockTitan

Dec 13, 2024
pulisher
Dec 04, 2024

Fortress Biotech (FRA:CNB1) EV-to-Revenue : 0.52 (As of Dec. 04, 2024) - GuruFocus.com

Dec 04, 2024
pulisher
Dec 02, 2024

Biotech Stocks Facing FDA Decision In December 2024 - RTTNews

Dec 02, 2024
pulisher
Dec 01, 2024

Fortress Biotech (STU:CNB1) Dividend Payout Ratio : 0.00 (As of Sep. 2024) - GuruFocus.com

Dec 01, 2024
pulisher
Nov 30, 2024

Fortress Biotech (STU:CNB1) 3-Year Dividend Growth Rate : 0.00% (As of Sep. 2024) - GuruFocus.com

Nov 30, 2024
pulisher
Nov 28, 2024

Loungers accepts £340m takeover by Fortress - Verdict Foodservice

Nov 28, 2024
pulisher
Nov 26, 2024

Fortress Biotech, Inc. (NASDAQ:FBIO) Shares Sold by GSA Capital Partners LLP - Defense World

Nov 26, 2024
pulisher
Nov 23, 2024

FBIOP.PFD (Fortress Biotech) Earnings Yield % : N/A% (As of Nov. 23, 2024) - GuruFocus.com

Nov 23, 2024
pulisher
Nov 22, 2024

(FBIOP) Trading Signals - Stock Traders Daily

Nov 22, 2024
pulisher
Nov 22, 2024

Fortress Biotech (FRA:CNB0.PFD) Total Liabilities : €125.98 Mil (As of Sep. 2024) - GuruFocus.com

Nov 22, 2024
$79.89
price up icon 2.27%
$32.25
price up icon 1.67%
$4.47
price down icon 5.10%
$353.31
price up icon 2.22%
biotechnology ONC
$221.22
price up icon 0.71%
$114.50
price down icon 0.67%
Cap:     |  Volume (24h):